Literature DB >> 9225873

Avascular necrosis of bone in systemic lupus erythematosus. The predictive role of precipitating autoantibodies.

T Watanabe1, T Tsuchida, N Kanda, K Tamaki.   

Abstract

The association between the type of precipitating autoantibodies and occurrence of avascular necrosis of bone (AVN) was examined. We prospectively analyzed clinical and laboratory findings of our 113 patients with SLE. Seven of 113 (6%) patients developed AVN. Anti-Ro (SS-A) and anti-RNP antibodies coexisted in 3 of 7 AVN patients. The same combination of these two antibodies were observed in 1 without AVN. Antibodies to topoisomerase I were detected in 2 other patients with AVN but not in any of the patients without AVN. The coexistence of the former two or the presence of the latter one is rare in SLE. However, these (combination of) antibodies can be useful as a local ischemic marker predicting the development of AVN.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9225873     DOI: 10.3109/03009749709065679

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  3 in total

1.  Anti-topoisomerase I antibodies in systemic lupus erythematosus as a marker of severe nephritis.

Authors:  Mohamed A Hamidou; Marie A Audrain; Agathe Masseau; Christian Agard; Anne Moreau
Journal:  Clin Rheumatol       Date:  2006-03-07       Impact factor: 2.980

2.  The risk factors of avascular necrosis in patients with systemic lupus erythematosus: a meta-analysis.

Authors:  Kao-Kao Zhu; Wang-Dong Xu; Hai-Feng Pan; Min Zhang; Jing Ni; Fu-Yang Ge; Dong-Qing Ye
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

3.  Comparison of clinical outcomes by different renal replacement therapy in patients with end-stage renal disease secondary to lupus nephritis.

Authors:  Seok-Hui Kang; Byung-Ha Chung; Sun-Ryoung Choi; Ja-Young Lee; Hoon-Suk Park; In-O Sun; Bum-Soon Choi; Cheol-Whee Park; Yong-Soo Kim; Chul-Woo Yang
Journal:  Korean J Intern Med       Date:  2011-03-02       Impact factor: 3.165

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.